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Glomerular 
Dysfunction: 
Decrease GRF
Various pathophysiologic pathways 
lead to:
 Renal tissue mesangial cell changes
 Extracellular matrix production
 Cellular oxidative stress
 Cellular destruction
 Increase vascular permeability
 Hyperfiltration
 Albuminuria.
 All of which causes:
Investigating the pathophysiology 
underlying DKD has allowed advanced 
nurse practitioners to adequately screen 
patient with diabetes for albuminuria 
prior to overt clinical symptomology.
Glycemic control is paramount to the 
treatment of the diabetic patient in order 
to stall the progression of kidney disease.
The National Kidney Foundation 
(2015) recommends annual screening 
for patients with diabetes to include Hgb
A1C, blood pressure, BUN, creatinine, 
and urine albumin levels. Treatment for 
high blood pressure with ACE inhibitors 
or ARBs  to interrupt the renin-
angiotensin-aldosterone system (RAAS) 
is also recommended. 
Pt education regarding the need for 
glycemic and blood pressure control is 
also needed. Advanced practitioners 
must address diet as a means of not only 
glycemic control, but also as a major 
influence on blood pressure levels, and 
obesity. 
Diabetic Kidney Disease (DKD) 
formerly known as diabetic 
nephropathy is the most common 
cause of end-stage renal disease 
(ESRD) and death in patient with 
diabetes (Fox, 2012; Himmelfarb, & 
Tuttle, 2013).
More than 100,00 people are 
diagnosed with chronic kidney disease 
in the United Sates annually.  More 
than 20 million (or 1 in 10 Americans) 
are currently living with some level of 
chronic kidney disease  (National 
Institute of Diabetes and Digestive and 
Kidney Diseases [NIDDK], 2016).
44% of newly diagnosed cases of 
chronic kidney disease are caused by 
diabetes (NIDDK,  2016).
DKD in the US population has risen 
from 2.2% to 3.3% from1998 to 2008 
(Fox, 2012), while those receiving 
treatment for ESRD has increased 18 
fold from 1980 to 2008 (Toth-
Manikowski, & Atta, 2015)
The annual cost of DKD in the United 
states in 2009 was estimated at $18 
billion (Reutens, 2013). This cost rose 
to over $40 billion by 2009 (NIDDK, 
2016).
At risk populations include African 
Americans, American Indians, and 
Hispanics/Latinos, all of whom 
develop diabetes and chronic kidney 
disease at higher rates than 
Caucasians. As of now, the scientific 
community is able to say why these 
groups are more at risk. However, it is 
thought to be an interplay of heredity, 
diet, and comorbid conditions. High 
blood pressure and hyperglycemia 
increase the risk of developing DKD 
(NIDDK, 2016).
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Table 1. KDOQI (2002)*clinical practice guidelines for chronic kidney 
disease with clinical presentation. * no change with update in 2015; 
http://www2.kidney.org/professionals/kdoqi/guidelines_ckd/p9-approach/html
Nursing Implications
It is well documented that DKD not 
only creates a large financial burden on 
the United States, but greatly adds to the 
morbidity and mortality of the patient 
with diabetes. DKD is a complex interplay 
of various pathophysiologic mechanisms. 
The advanced nurse practitioner must 
fully understand the mechanism at play 
in DKD and the resulting insult to the 
renal tissue.  This understanding allows 
the advanced nurse practitioner to 
properly educate and treat patients at 
risk for DKD.
Conclusion
Understanding the complex 
interconnection of the pathophysiology 
of DKD will allow the advance nurse 
practitioner to appropriately treat the 
patient at risk for DKD. 
The pathophysiology includes 
cellular changes brought on by genetic 
factors, dysfunction in the glycolysis 
pathways,  renal mesangial changes, 
extracellular matric production, 
oxidative stress and destruction, 
increased vascular permeability and 
hyperfiltration. These mechanisms 
generate the resulting albuminuria and 
decreasing GFR that are hallmark for 
DKD..
Significance of 
Pathophysiology
Genetic Factors: ESRD-
associated single nucleotide 
polymorphism (SNP) found by 
GENIE study:  an intronic
SNPAF4/FMR2 family member 3; 
and an intergenic SNP on 
chromosome 15q26 (rs12437854) 
(Reidy, et al., 2014).  Sharma, et al 
(2013) found that kidney tissue 
from DKD patients had less 
mitochondrial DNA, and lower gene 
expression of PGC1-a, a regulator of 
mitochondrial biogenesis. The 
researchers also found 12 urine 
metabolite that support suppression 
of mitochondrial metabolism.
Histologic Changes: At the 
cellular level, expansion in the 
mesangial cells form a thickened 
basement membrane. In turn, there 
is hyperfiltration and 
glomerulosclerosis with 
Kimmelsteil-Wilson nodules. 
Hypertrophic changes in podocytes 
allow for increased filtration of 
albumin (Reidy, Kang, Hostetter, & 
Susztak, 2014; Toth- Manikowski, & 
Atta, 2015). These changes have 
been attributed to diabetic 
angiopathy, aging, atherosclerosis, 
hypertension, and episodes of acute 
kidney injury (Toth-Mankowski, & 
Atta, 2015).
Hemodynamic Changes: 
Hemodynamically, there is an 
elevation of Angiotensin II and 
Endothein-1 (ET-1) which results in 
changes in mesangial cells and 
extracellular matrix production that 
increase vascular permeability and 
hyperfiltration, increasing 
inflammation, and hypertension 
(Toth- Manikowski, & Atta, 2015).   
Pathophysiologic Processes
Metabolic Changes: Four metabolic 
pathways were noted by Toth-Mankowski 
and Atta (2015) that are upregulated due 
to increasing glycolysis of hyperglycemia. 
These pathway (the polyol pathway, the 
hexamine pathway, advances glycation end 
products, and PKC pathway) result in 
damage to the renal system in some 
manner. 
Polyol Pathway is upregulated due to 
hyperglycemia. Glucose is normally 
converted to sorbitol via the NADPH-
dependent enzyme aldose reductase, and is 
then converted to fructose. When 
upregulated, the polyol pathway the 
reduction of glucose to sorbitol at a higher 
rate results in decreased intercellular 
NADPH. In turn the antioxidant glutathione 
is decreased, contributing to increased 
intracellular oxidative stress which may 
end in cellular apoptosis.
Hexosamine pathway stems from the third 
step of glycolysis that results in production 
of glucosamine-6-phosphate, which is used 
as a substrate to increase transcription of 
inflammatory cytokines: tumor necrosis 
factors-a (TNF-a) (see AGEs below) and 
transforming growth factor-b1 (TGF-b1). 
TGF-b1 promote renal cell hypertrophy and 
increased mesangial matrix components.
Production of advanced glycation end 
products (AGEs) result from irreversible 
glycation of proteins that are present with 
intercellular hyperglycemia. AGEs damage 
cells by modifying protein function that 
leads to increased permeability of 
glomerular basement membrane, 
expansion of the renal extracellular matrix , 
and  increasing pro-inflammatory cytokines 
(IL-1, IL-6, TMF-a).
Activation pf protein kinase C (PKC) stems 
from the 4th step of glycolysis. PKC 
increases activity of prostaglandin E2, and 
NO leading to vasodilation, contributing to 
glomerular hyperfiltration.
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Figure 2: Effects of Angiotensin II and Endothelin I 
http://ajpregu.physiology.org/content/310/10/R877.figures-
only
The diagnosis of kidney disease is 
made by measuring albumin levels in 
the urine (albuminuria). However, this 
is detected long before the patient 
shows any overt signs of kidney 
disease. Albuminuria is classified by 
the amount in urine in a 24 hour 
period. Microalbuminuria is 30-300 
mg of albumin, while 
macroalbuminuria is greater than 300 
mg (National Kidney Foundation, 
2009).
Glomerular filtration rate (GFR) is also 
calculated in order to monitor the 
function of the kidney (see Table 1).
Other signs and symptoms that the 
patient may notice earlier in the 
disease process are weight gain and 
ankle swelling. Later signs and 
symptoms are described below 
(National Kidney foundation, 2015).
Figure 1: Glomerular changes related to underlying pathophysiology. Retrieved from: http://www.kidney-
international.org/cms/attachment/2043439544/2056050861/gr3.jpg
